Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX EBITDA Margin

EBITDA as a percentage of revenue.

Janux Therapeutics, Inc.NASDAQ: JANX

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin at -640.0%

EBITDA Margin was -640.0% in Q1 FY2026. On a trailing-twelve-month basis it was -520.3%, up 290.5 pp year over year. Over 3 fiscal years it narrowed by 393.5 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 11 analysts of -331.3% for the fiscal year ending Dec 2026, up from -1116.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-640.0%-241.2 pp QoQ
Last fiscal yearDec 2025
-1116.0%-483.8 pp YoY
LTMMar 2026
-520.3%+290.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-483.8 pp+784.7 pp+1268.5 pp
3 years-393.5 pp-1940.1 pp-1546.6 pp
5 years+972.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1116.0%
Year-over-year change
-483.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How JANX compares with its peers on the latest reported figures

  • JANX's LTM Mar 2026 EBITDA Margin of -520.3% is the 5th highest of the 8 companies compared; the peer median is -162.2%.
  • Its year-over-year change of +290.5 pp is the highest of 8, against a peer median of -191.7 pp.
  • Over three fiscal years its change of -393.5 pp compares with a peer median of +22.5 pp.
JANX Competitors Peer median
EBITDA Margin for JANX and competitors
Company Period LTM level YoY 3-year change
LEGNLegend Biotech CorporationLTM Sep 20267.3% +27.5 pp+333.4 pp
MGNXMacroGenics, Inc.LTM Mar 2026-32.2% -1.2 pp+32.0 pp
STROSutro Biopharma, Inc.LTM Mar 2026-106.5% +169.1 pp+12.9 pp
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-162.2% -191.7 pp+161.5 pp
JANXJanux Therapeutics, Inc.LTM Mar 2026-520.3% +290.5 pp-393.5 pp
IMTXImmatics N.V.LTM Mar 2026-542.7% -539.6 pp-412.4 pp
IMNMImmunome, Inc.FY2025-3017.4% -1343.3 pp—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-272652.7% -264146.9 pp-12607.1 pp
CGEMCullinan Therapeutics, Inc.FY2025— ——
VRXAVeraxa Biotech Holding AG—— ——
CMPXCompass Therapeutics, Inc.FY2025— ——
Peer median (excluding JANX) -162.2%-191.7 pp+22.5 pp

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.64M8.61M8.08M10.59M10M
Cost of Revenue26.24M841K1.96M2.06M2.03M
Gross Profit(22.6M)7.77M6.13M8.53M7.97M
Gross Margin-621.4%90.2%75.8%80.5%79.7%
Research & Development26.24M53.44M54.92M68.39M125.9M
Selling, General & Admin10.33M22.26M26.14M41.05M41.77M
Operating Expenses10.33M74.86M79.11M107.38M165.64M
Depreciation & Amortization113K841K1.96M2.06M2.03M
EBITDA(32.56M)(62.22M)(56.34M)(66.93M)(111.6M)
EBITDA Margin-895.2%-722.5%-697.0%-632.2%-1116.0%
Operating Income(32.93M)(67.09M)(72.98M)(98.85M)(157.67M)
Operating Margin-905.4%-779.0%-902.9%-933.6%-1576.7%
Interest Income257K4.03M14.69M29.85M44.04M
Interest Expense00000
Other Income / Expenses257K4.03M14.69M29.85M44.04M
Income Before Tax(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Pre-Tax Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
Income Tax Expense00000
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Net Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
EPS (Basic)(0.79)(1.52)(1.32)(1.28)(1.83)
EPS (Diluted)(0.79)(1.52)(1.32)(1.28)(1.83)
Weighted Avg Shares41.24M41.47M44.02M53.75M61.97M
Weighted Avg Shares (Diluted)41.24M41.47M44.02M53.75M61.97M

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.